A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta-Reference-Cited by-同舟云学术

A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta

Published:2009-12-18 Issue:1 Volume:25 Page:32-40
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Bishop Nick,Harrison Rachel,Ahmed Faisal,Shaw Nick,Eastell Richard,Campbell Mike,Knowles Elizabeth,Hill Claire,Hall Christine,Chapman Steve,Sprigg Alan,Rigby Alan

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference18 articles.

1. Treatment of children with osteogenesis imperfecta;Rauch;Curr Osteoporos Rep.,2006

2. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study;Sakkers;Lancet.,2004

3. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement;Letocha;J Bone Miner Res.,2005

4. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study;Gatti;J Bone Miner Res.,2005

5. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I;Ward;J Clin Endocrinol Metab.,2005

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta;Calcified Tissue International;2024-03-29

2. Clinical Characteristics and Therapeutic Management of Osteogenesis Imperfecta in Iraqi Children;Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 );2023-12-22

3. Osteogenesis Imperfecta Type 3 in a 10-Year-Old Child With Acute Respiratory Distress Syndrome;Cureus;2022-02-14

4. 4PBA reduces growth deficiency in osteogenesis imperfecta by enhancing transition of hypertrophic chondrocytes to osteoblasts;JCI Insight;2022-02-08

5. Drug Treatment of Low Bone Mass and Other Bone Conditions in Pediatric Patients;Pediatric Drugs;2022-01-11